lnu.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Innate Immune Invisible Ultrasmall Gold Nanoparticles-Framework for Synthesis and Evaluation
Univ Cambridge, UK.
Linköping University, Sweden.
Univ Oslo, Norway.
Univ Cambridge, UK.
Show others and affiliations
2021 (English)In: ACS Applied Materials and Interfaces, ISSN 1944-8244, E-ISSN 1944-8252, Vol. 13, no 20, p. 23410-23422Article in journal (Refereed) Published
Abstract [en]

Nanomedicine is seen as a potential central player in the delivery of personalized medicine. Biocompatibility issues of nanoparticles have largely been resolved over the past decade. Despite their tremendous progress, less than 1% of applied nanosystems can hit their intended target location, such as a solid tumor, and this remains an obstacle to their full ability and potential with a high translational value. Therefore, achieving immune-tolerable, blood-compatible, and biofriendly nanoparticles remains an unmet need. The translational success of nanoformulations from bench to bedside involves a thorough assessment of their design, compatibility beyond cytotoxicity such as immune toxicity, blood compatibility, and immune-mediated destruction/rejection/clearance profile. Here, we report a one-pot process-engineered synthesis of ultrasmall gold nanoparticles (uGNPs) suitable for better body and renal clearance delivery of their payloads. We have obtained uGNP sizes of as low as 3 nm and have engineered the synthesis to allow them to be accurately sized (almost nanometer by nanometer). The synthesized uGNPs are biocompatible and can easily be functionalized to carry drugs, peptides, antibodies, and other therapeutic molecules. We have performed in vitro cell viability assays, immunotoxicity assays, inflammatory cytokine analysis, a complement activation study, and blood coagulation studies with the uGNPs to confirm their safety. These can help to set up a long-term safety-benefit framework of experimentation to reveal whether any designed nanoparticles are immune-tolerable and can be used as payload carriers for next-generation vaccines, chemotherapeutic drugs, and theranostic agents with better body clearance ability and deep tissue penetration.

Place, publisher, year, edition, pages
American Chemical Society (ACS) , 2021. Vol. 13, no 20, p. 23410-23422
Keywords [en]
ultrasmall nanoparticles, process engineering, immunocompatibility, complement-safe, coagulation-safe, pro-inflammatory cytokine, biocompatibility
National Category
Materials Chemistry
Research subject
Chemistry, Biochemistry
Identifiers
URN: urn:nbn:se:lnu:diva-105828DOI: 10.1021/acsami.1c02834ISI: 000657202500009PubMedID: 33978409Scopus ID: 2-s2.0-85106349706Local ID: 2021OAI: oai:DiVA.org:lnu-105828DiVA, id: diva2:1580099
Available from: 2021-07-13 Created: 2021-07-13 Last updated: 2023-01-24Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMedScopus

Authority records

Nilsson, Per H.

Search in DiVA

By author/editor
Das, JyotirmoyNilsson, Per H.Patra, Hirak K.
By organisation
Department of Chemistry and Biomedical SciencesAdvanced Materials
In the same journal
ACS Applied Materials and Interfaces
Materials Chemistry

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 76 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf